- CMT2F Study Achieves Recruitment Goal, Expands to Include Additional Participants
An international team of researchers from the Inherited Neuropathies Consortium (INC), led by CMTA’s Strategy To Accelerate Research (CMTA-STAR) Advisory Board Member Michael Shy, MD, at the University of Iowa, has successfully reached full enrollment ...
Read more ... - CMTA Announces Its First Center of Excellence in Scotland
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to announce the designation of Katie Brennan, MD, PhD, at Queen Elizabeth University Hospital (QEUH) in Glasgow, Scotland, as ...
Read more ... - Accelerating Genetic Therapy for CMT4B1: A CMTA Research Update
With CMTA’s support, researchers at San Raffaele Scientific Institute in Milan, Italy, led by Alessandra Bolino, PhD, are making significant progress in developing an AAV9-based genetic therapy for CMT4B1. This $380,000 CMTA Strategy To Accelerate ...
Read more ... - CMTA’s $300K Investment in CRISPR for CMT2A
The Charcot-Marie-Tooth Association (CMTA) is investing $300,000 in a groundbreaking gene editing research project at Gladstone Institutes to develop a CRISPR-based therapy for CMT2A. This CMTA Strategy To Accelerate Research (CMTA-STAR) initiative aims to create ...
Read more ... - What’s New in CMT Research and Care? A 2025 Update Published by CMTA-STAR Advisory Board Member Davide Pareyson, MD
CMTA Strategy To Accelerate Research (CMTA-STAR) Advisory Board member and clinic director of the CMTA Center of Excellence at the C. Besta Neurological Institute in Milan, Italy, Davide Pareyson, MD, and colleagues review the latest ...
Read more ...